Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more
Galapagos NV (GLPGF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.022x
Based on the latest financial reports, Galapagos NV (GLPGF) has a cash flow conversion efficiency ratio of -0.022x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.61 Million) by net assets ($2.88 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Galapagos NV - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Galapagos NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Galapagos NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Sports Industry Group Co Ltd
SHG:600158
|
-0.011x |
|
Coastal Financial Corp
NASDAQ:CCB
|
0.120x |
|
Perpetual Ltd
AU:PPT
|
0.119x |
|
Koh Young Technology Inc
KQ:098460
|
0.000x |
|
HeiLongJiang Kingland Technology Co Ltd
SHE:000711
|
-0.015x |
|
Caida Securities Co Ltd
SHG:600906
|
0.029x |
|
Terveystalo Oy
HE:TTALO
|
0.057x |
|
InventisBio Co. Ltd. A
SHG:688382
|
N/A |
Annual Cash Flow Conversion Efficiency for Galapagos NV (2004–2024)
The table below shows the annual cash flow conversion efficiency of Galapagos NV from 2004 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.90 Billion | $-320.03 Million | -0.110x | +23.93% |
| 2023-12-31 | $2.80 Billion | $-405.97 Million | -0.145x | +26.71% |
| 2022-12-31 | $2.53 Billion | $-500.54 Million | -0.198x | -3.96% |
| 2021-12-31 | $2.64 Billion | $-503.83 Million | -0.191x | -19.10% |
| 2020-12-31 | $2.67 Billion | $-427.34 Million | -0.160x | -114.34% |
| 2019-12-31 | $2.88 Billion | $3.21 Billion | 1.116x | +1050.99% |
| 2018-12-31 | $1.21 Billion | $-142.47 Million | -0.117x | +19.24% |
| 2017-12-31 | $1.01 Billion | $-147.03 Million | -0.145x | -146.04% |
| 2016-12-31 | $758.70 Million | $239.40 Million | 0.316x | +200.51% |
| 2015-12-31 | $365.00 Million | $-114.59 Million | -0.314x | +14.35% |
| 2014-12-31 | $206.13 Million | $-75.56 Million | -0.367x | -11835.82% |
| 2013-12-31 | $167.14 Million | $522.00K | 0.003x | -99.42% |
| 2012-12-31 | $118.45 Million | $64.10 Million | 0.541x | +634.28% |
| 2011-12-31 | $118.38 Million | $-11.99 Million | -0.101x | +19.01% |
| 2010-12-31 | $148.51 Million | $-18.57 Million | -0.125x | -316.03% |
| 2009-12-31 | $108.88 Million | $6.30 Million | 0.058x | +159.47% |
| 2008-12-31 | $84.32 Million | $-8.21 Million | -0.097x | -2687.95% |
| 2007-12-31 | $98.63 Million | $371.00K | 0.004x | +104.43% |
| 2006-12-31 | $109.54 Million | $-9.31 Million | -0.085x | -33.68% |
| 2005-12-31 | $61.14 Million | $-3.89 Million | -0.064x | +75.68% |
| 2004-12-31 | $10.37 Million | $-2.71 Million | -0.261x | -- |